[1]廖丹,许立帅,戴乐,等.577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2018,38(2):139-142.[doi:10.13389/j.cnki.rao.2018.0030]
　LIAO Dan,XU Li-Shuai,DAI Le,et al.Subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy with foveal leakage[J].Recent Advances in Ophthalmology,2018,38(2):139-142.[doi:10.13389/j.cnki.rao.2018.0030]
点击复制

577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年2期
页码:
139-142
栏目:
应用研究
出版日期:
2018-02-05

文章信息/Info

Title:
Subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy with foveal leakage
作者:
廖丹; 许立帅; 戴乐; 杨祯; 杨小丽
637000　四川省南充市，川北医学院附属医院眼科
Author(s):
LIAO Dan; XU Li-Shuai; DAI Le; YANG Zhen; YANG Xiao-Li
Department of Ophthalmology，the Affiliated Hospital of North Sichuan Medical College，Nanchong 637000，Sichuan Province，China
关键词:
阈下微脉冲激光; 慢性中心性浆液性脉络膜视网膜病变; 中心凹渗漏
Keywords:
subthreshold micropulse yellow laser; chronic central serous chorioretinopathy; foveal leakage
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2018.0030
文献标志码:
A
摘要:
目的　观察577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变（central serous chorioretinopathy，CSC）的疗效。方法　本研究纳入12例12眼确诊为病灶在黄斑中心凹的慢性CSC患者，均使用577 nm阈下微脉冲激光对渗漏点及其周围进行多点覆盖性光凝。治疗后1周、1个月、3个月及6个月评估最佳矫正视力、黄斑中心凹视网膜厚度和视网膜下液（subretinal fluid，SRF）消退情况。结果　治疗后6个月，最佳矫正视力由治疗前的（0.27±0.08）logMAR提高到（0.19±0.11）logMAR，差异具有统计学意义（P=0.016）；黄斑中心凹视网膜厚度由治疗前的（432.42±134.17）μm下降到（248.75±36.06）μm，差异具有统计学意义（P=0.002）；SRF高度由治疗前的（213.58±132.60）μm下降到（17.25±21.90）μm，差异具有统计学意义（P=0.002）。末次随访时，6眼的SRF已经完全消失，6眼仍然有SRF的积存，但较治疗前有缓解的趋势。随访6个月，所有患眼均未见视网膜或脉络膜损伤。结论　577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性CSC安全有效。
Abstract:
Objective　To assess the safety and efficacy of subthreshold micropulse yellow laser (577 nm) in the treatment of chronic central serous chorioretinopathy with foveal leakage.Methods　This was a prospective study of 12 patients (12 eyes) with chronic central serous chorioretinopathy (CSC).All patients had been treated using multiple spots of subthreshold micropulse yellow laser at 577 nm with a duty cycle of 5% over areas of focal and diffuse leakage.And 1weeks，1 months，3 months，and 6 months after treatment，the best corrected visual acuity (BCVA)，central macular thickness (CMT) and reduction in subretinal fluid (SRF) were recorded.Results　The mean BCVA measured at 6 months after laser treatment was 0.19±0.11，which was in comparison to 0.27±0.08 before laser treatment，and the difference was statistically significant (P=0.016).The mean CMT was significantly reduced from (432.42±134.17)μm before laser treatment to (248.75±36.06)μm after 6 months (P=0.002).The mean SRF height was significantly decreased from (213.58±132.60)μm at baseline to (17.25±21.90)μm (P=0.002).At the last follow-up，the SRF had disappeared completely in 6 out of 12 eyes，but there were still 6 eyes suffering from SRF.There was no evidence of retinal or choroidal damage during 6-month follow up.Conclusion　Subthreshold micropulse yellow laser (577 nm) is an effective treatment option for chronic CSC with foveal leakage.

参考文献/References:

［1］　WANG M，MUNCH IC，HASLER PW，PRUNTE C，LARSEN M.Central serous chorioretinopathy［J］.Acta Ophthalmol，2008，86（2）：126-145.
［2］　LIEW G，QUIN G，GILLIES M，FRASER-BELL S.Central serous chorioretinopathy：a review of epidemiology and pathophysiology［J］.Clin Exp Ophthalmol，2013，41（2）：201-214.
［3］　GEMENETZI M，DE SALVO G，LOTERY AJ.Central serous chorioretinopathy：an update on pathogenesis and treatment［J］.Eye （Lond），2010，24（12）：1743-1756.
［4］　LOO RH，SCOTT IU，FLYNN HW，GASS JD，MURRAY TG，LEWIS ML，et al.Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy［J］.Retina，2002，22（1）：19-24.
［5］　BUJARBORUA D.Long-term follow-up of idiopathic central serous chorioretinopathy without laser［J］.Acta Ophthalmol Scand，2001，79（4）：417-421.
［6］　CHAN WM，LAI TY，LAI RY，TANG EW，LIU DT，LAM DS.Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy：one-year results of a prospective study［J］.Retina，2008，28（1）：85-93.
［7］　YANNUZZI LA.Central serous chorioretinopathy：a personal perspective［J］.Am J Ophthalmol，2010，149（3）：361-363.
［8］　KHOSLA PK，RANA SS，TEWARI HK，AZAD RU，TALWAR D.Evaluation of visual function following argon laser photocoagulation in central serous retinopathy［J］.Ophthalmic Surg Lasers，1997，28（8）：693-697.
［9］　OBER MD，YANNUZZI LA，DO DV，SPAIDE RF，BRESSLER NM，JAMPOL LM，et al.Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy［J］.Ophthalmology，2005，112（12）：2088-2094.
［10］　SCHOLZ P，ERSOY L，BOON CJ，FAUSER S.Subthreshold micropulse laser （577 nm） treatment in chronic central serous chorioretinopathy［J］.Ophthalmologica，2015，234（4）：189-194.
［11］　CHUNG YR，SEO EJ，LEW HM，LEE KH.Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy：meta-analysis and review［J］.Eye （Lond），2013，27（12）：1339-1346.
［12］　LAI TY，CHAN WM，LAM DS.Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy［J］.Am J Ophthalmol，2004，137（5）：826-833.
［13］　YAMAN A，ARIKAN G，SAATCI AO，CINGIL G.Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy［J］.Bull Soc Belge Ophtalmol，2007，（303）：69-73.
［14］　LANZETTA P，DORIN G，PIRRACCHIO A，BANDELLO F.Theoretical bases of non-ophthalmoscopically visible endpoint photocoagulation［J］.Semin Ophthalmol，2001，16（1）：8-11.
［15］　CHEN SN，HWANG JF，TSENG LF，LIN CJ.Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage［J］.Ophthalmology，2008，115（12）：2229-2234.
［16］　YADAV NK，JAYADEV C，RAJENDRAN A，NAGPAL M.Recent developments in retinal lasers and delivery systems［J］.Indian J Ophthalmol，2014，62（1）：50-54.
［17］　YADAV NK，JAYADEV C，MOHAN A，VIJAYAN P，BATTU R，DABIR S，et al.Subthreshold micropulse yellow laser （577 nm） in chronic central serous chorioretinopathy：safety profile and treatment outcome［J］.Eye （Lond），2015，29（2）：258-264.
［18］　ABD ELHAMID AH.Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy［J］.Clin Ophthalmol，2015，9：2277-2283.
［19］　JOONDEPH BC，JOONDEPH HC，BLAIR NP.Retinal macroaneurysms treated with the yellow dye laser［J］.Retina，1989，9（3）：187-192.
［20］　OZMERT E，DEMIREL S，YANIK O，BATIOGLU F.Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy［J］.J Ophthalmol，2016，2016：3513794.
［21］　SCHOLZ P，ALTAY L，FAUSER S.Comparison of subthreshold micropulse laser （577 nm） treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy［J］.Eye （Lond），2016，30（10）：1371-1377.
［22］　LANZETTA P，FURLAN F，MORGANTE L，VERITTI D，BANDELLO F.Nonvisible subthreshold micropulse diode laser （810 nm） treatment of central serous chorioretinopathy.A pilot study［J］.Eur J Ophthalmol，2008，18（6）：934-940.
［23］　WANG MS，SANDER B，LARSEN M.Retinal atrophy in idiopathic central serous chorioretinopathy［J］.Am J Ophthalmol，2002，133（6）：787-793.
［24］　XIE WH，LI YJ，XIANG DM，CHEN F，CHEN ZS，LIU PZ，et al.Changes in serum levels of stress factors before and after laser therapy for retinopathy of prematurity［J］.Chin J Appl Clin Pediatr，2014，29（10）：765-768.
谢婉花，李亚洁，项道满，陈锋，陈正珊，刘佩珍，等.激光治疗早产儿视网膜病患儿手术前后血浆应激因子水平的变化［J］.中华实用儿科临床杂志，2014，29（10）：765-768.

相似文献/References:

[1]李娟娟 李燕.慢性中心性浆液性脉络膜视网膜病变视网膜色素上皮细胞萎缩轨迹的临床观察[J].眼科新进展,2013,33(8):000.
[2]吴敏,胡竹林,薛黎萍,等. 半剂量维替泊芬和半能量PDT治疗慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2015,35(7):646.[doi:10.13389/j.cnki.rao.2015.0176]
　WU Min,HU Zhu-Lin,XUE Li-Ping,et al. Half-dose verteporfin and half laser power PDT for chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2015,35(2):646.[doi:10.13389/j.cnki.rao.2015.0176]
[3]马为梅,雷晓琴,田芳,等.半剂量维替泊芬与半能量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2017,37(4):341.[doi:10.13389/j.cnki.rao.2017.0086]
　MA Wei-Mei,LEI Xiao-Qin,TIAN Fang,et al.Half-dose verteporfin and half-fluence photodynamic therapy for chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2017,37(2):341.[doi:10.13389/j.cnki.rao.2017.0086]
[4]陈莲,何珂,李晓清,等.非那雄胺在慢性中心性浆液性脉络膜视网膜病变患者中的应用[J].眼科新进展,2020,40(5):474.[doi:10.13389/j.cnki.rao.2020.0109]
　CHEN Lian,HE Ke,LI Xiaoqing,et al.Clinical effect of Finasteride on chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2020,40(2):474.[doi:10.13389/j.cnki.rao.2020.0109]
[5]肖艳辉,刘高勤,夏蔚.慢性中心性浆液性脉络膜视网膜病变与息肉样脉络膜血管病变多模式影像学特征的比较[J].眼科新进展,2020,40(12):1139.[doi:10.13389/j.cnki.rao.2020.0253]
　XIAO Yanhui,LIU Gaoqin,XIA Wei.Multimodal imaging comparison of chronic central serous chorioretinopathy and polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2020,40(2):1139.[doi:10.13389/j.cnki.rao.2020.0253]

备注/Memo

备注/Memo:
四川省教育厅重点项目（编号：17ZA0171）
更新日期/Last Update: 2018-02-02